Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
In two patients with end stage renal disease and dialysis-resistant hypertension, the orally active inhibitor of angiotensin-converting enzyme, captopril (SQ14,225; 2-D-methyl-3-mercaptopropranoyl-L-proline, dramatically lowered blood pressure both before and during dialysis. This agent holds promise as an alternate to bilateral nephrectomy in such patients.
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009400:Nephrosclerosis / Q000150:complications; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006435:Renal Dialysis
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011392:Proline